Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Welby Inc. (4438.T)
Tokyo, JP
Established in Tokyo, Japan, in 2011, Welby Inc. specializes in developing digital healthcare solutions aimed at enhancing patients' access to and engagement with medical services. The company's extensive portfolio addresses a wide array of health conditions, encompassing diabetes mellitus, lifestyle-related diseases, mental health disorders, autoimmune and neurological diseases, rare conditions, oncology, and pain management. Furthermore, Welby is active in medical data surveying and operates its signature platform, Welby My Carte.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.71% | -3.73% | -14.46% | +1.79% | -9.27% | +0.71% | -18.62% | -43.09% | -74.80% | -93.56% | -93.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+20.4% ★ Q1'26: +10.7% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+33.8% Q1'26: +9.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-57.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-71.2% Q1'26: -118.1% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%-225.7% Q1'26: -270.1% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+1.4% Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-1.43× Q1'26: -0.89× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
798.52M
est: 1.08B (-26.3%)
|
864.64M
est: 1.10B (-21.7%)
|
1.14B
est: 1.09B (+4.6%)
|
1.05B
est: 1.35B (-22.1%)
|
575.00M
est: 1.59B (-63.8%)
|
528.04M
est: 1.83B (-71.1%)
|
635.72M
est: 635.72M (+0.0%)
|
| EBITDA |
3.47M
est: -498.39M (+100.7%)
|
-309.28M
est: -508.05M (+39.1%)
|
-127.70M
est: -501.15M (+74.5%)
|
40.29M
est: -621.26M (+106.5%)
|
-499.97M
est: -731.71M (+31.7%)
|
-792.75M
est: -955.09M (+17.0%)
|
-423.57M
est: -331.79M (-27.7%)
|
| EBIT |
-4.51M
est: -505.63M (+99.1%)
|
-331.70M
est: -515.44M (+35.6%)
|
-128.30M
est: -508.43M (+74.8%)
|
38.20M
est: -630.29M (+106.1%)
|
-502.84M
est: -742.34M (+32.3%)
|
-815.31M
est: -974.69M (+16.4%)
|
-452.83M
est: -338.60M (-33.7%)
|
| Net Income |
-11.30M
est: 167.27M (-106.8%)
|
-353.09M
est: 16.32M (-2,263.7%)
|
-130.68M
est: -312.51M (+58.2%)
|
33.91M
|
-505.00M
est: 35.09M (-1,539.3%)
|
-804.60M
est: 64.55M (-1,346.5%)
|
-539.69M
|
| SGA |
602.34M
est: 1.21B (-50.1%)
|
732.16M
est: 1.23B (-40.5%)
|
796.72M
est: 1.21B (-34.4%)
|
692.68M
est: 1.51B (-54.0%)
|
813.00M
est: 1.77B (-54.2%)
|
1.03B
est: 2.25B (-54.1%)
|
901.50M
est: 781.76M (+15.3%)
|
| EPS |
-1.47
est: 20.50 (-107.2%)
|
-45.18
est: 2.00 (-2,359.0%)
|
-16.68
est: -38.30 (+56.4%)
|
4.33
|
-64.47
est: 4.30 (-1,599.3%)
|
-98.54
est: 7.80 (-1,363.3%)
|
-65.21
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takeru Hiki | Chief Executive Officer & Representative Director | — | male |
| Tetsuya Hayashi | Executive Officer & GM of Services Development Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4438.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
